Cullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data
I'm LongbridgeAI, I can summarize articles.Cullinan Therapeutics and Taiho announced that the Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC met its primary endpoint of progression-free survival. The combination showed significant clinical benefit with manageable safety, prompting unblinding. This milestone supports plans for U.S. regulatory approval. While analysts rate CGEM stock a Buy with a $30 target, AI analysis notes neutral sentiment due to weak financials despite positive pipeline updates.
Cullinan Management ( (CGEM) ) just unveiled an update.
On August 12, 2026, Cullinan Therapeutics and Taiho announced that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy in first-line treatment of EGFR exon 20 insertion-mutated non-small cell lung cancer met its primary endpoint of progression-free survival at a planned interim analysis. The combination arm demonstrated a statistically significant and clinically meaningful improvement in progression-free survival with manageable safety, prompting the Independent Data Monitoring Committee to recommend unblinding while the trial continues to monitor outcomes.
The positive interim results represent a key milestone for the zipalertinib program and reinforce the partners’ strategy in targeted oncology for a genetically defined NSCLC population with limited options. Cullinan and Taiho intend to seek U.S. regulatory approval for the combination regimen in the first-line setting following regulatory discussions and full data disclosure at an upcoming international medical conference, a move that could enhance their competitive standing and potentially broaden therapeutic choices for patients and clinicians.
The most recent analyst rating on (CGEM) stock is a Buy
with a $30.00 price target.
To see the full list of analyst forecasts on Cullinan Management stock,
see the CGEM Stock Forecast page.
Spark’s Take on CGEM Stock
According to Spark, TipRanks’ AI Analyst, CGEM is a Neutral.
Overall score is held back primarily by weak financial performance (no meaningful revenue, large losses, and significant cash burn with a declining equity base). Offsetting factors include a moderately positive technical trend (price above key moving averages with neutral momentum) and favorable recent clinical-stage pipeline updates, while valuation provides little support due to negative earnings and no dividend.
To see Spark’s full report on CGEM stock,
click here.
More about Cullinan Management
Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Leveraging expertise in T cell engagers and a clinical-stage pipeline, the company aims to establish new standards of care for patients in genetically and immunologically defined indications.
The company collaborates with Taiho Oncology and Taiho Pharmaceutical on the development of zipalertinib, an orally available, next-generation, irreversible EGFR inhibitor targeting exon 20 insertion mutations in non-small cell lung cancer. This partnership positions Cullinan within a competitive oncology niche focused on targeted therapies for molecularly defined subsets of NSCLC.
On August 12, 2026, Cullinan Therapeutics and Taiho announced that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy in first-line treatment of EGFR exon 20 insertion-mutated NSCLC met its primary endpoint of progression-free survival at a planned interim analysis. The combination arm showed a statistically significant and clinically meaningful improvement in progression-free survival with manageable safety, leading the Independent Data Monitoring Committee to recommend unblinding while the study continues to track efficacy and safety.
The positive topline data mark an important clinical milestone for zipalertinib and strengthen Cullinan’s and Taiho’s positioning in targeted lung cancer therapy, particularly for a subset of NSCLC with high unmet medical need. The partners plan to seek U.S. regulatory approval for the regimen in this first-line setting after discussions with regulators and presentation of full results at a future international medical conference, potentially expanding treatment options and supporting the companies’ oncology franchises.
Average Trading Volume: 975,900
Technical Sentiment Signal: Buy
Current Market Cap: $1.26B